A week before the Spring Festival (January 28 to February 1), a total of 35 companies in Shanghai and Shenzhen disclosedResearchRecord, many institutional investors are still busy on the road of research.
The Securities Times·e company reporter noticed that the research companies before the festival mostly disclosed the latest in recent days.PerformanceA company with a notice or performance report. Of the 32 companies that have disclosed their expected results, 26 are pre-increased companies for the annual report. among them,Zhuo Yi Technology,Suning Online MarketwithHudian sharesThe expected increase in net profit in 2018 is above 100%.
According to the research records, the organization pays close attention to the new information released by the listed company's 2018 annual results, so as to look forward to the development trend of various industries in 2019. In addition, the trend of the popular white horse stocks is still the focus of the organization's annual focus.
From the number of research institutions,Jinjia sharesMost favored. On the evening of January 28th, Jinjia shares issued a performance report. On the afternoon of January 29th, the company quickly held a conference call. A total of 78 institutions participated in the conference, attracting a number of star private equity investors such as Danshuiquan Investment, Chongyang Investment, and Shangya Investment. ".
The steady growth of the main business of Jinjia Shares is an important factor in attracting institutional attention. According to the performance report, the company achieved a total operating income of 3.373 billion yuan in 2018, an increase of 14.51% over the same period.Net profit727 million yuan, an increase of 26.49%. Benefiting from the overall good development trend of the tobacco industry in 2018, the company's cigarette sales revenue was about 2.6 billion yuan, an increase of 8.05%.
In the investigation, Jinjia shares introduced the strategic cooperation with Yunnan Tobacco and the company's new tobacco business. The company said that in August 2018, it signed a comprehensive strategic cooperation agreement with Yunnan Zhongyan on new tobacco. In the new tobacco business, Yunnan Zhongyan is in the forefront of the national tobacco company, how to strengthen cooperation with Yunnan Tobacco. An important direction for promotion as a partner. In addition, Jinjia Technology continues to invest in research and development of new tobacco products such as non-burning appliances and electronic cigarettes, and has obtained a number of valid patents in this field.
In terms of the development trend of the tobacco industry in 2019, Jinjia believes that in 2018, the tobacco industry is in line with the expected plan for the overall deployment of tobacco. From the current open profit and tax and inventory data, the basis of 2018 is good. Under the supply-side reform of the cigarette industry, both industrial and commercial inventories and social inventories have all declined. The company believes that the tobacco industry will continue its good momentum in 2019.
In addition,Han nationality laser,Sophia,Hikvision,Dahua shares,Mindray MedicalA number of white horse stocks also ushered in before the festivalInstitutional research. Among them, Han's Laser and Mindray Medical received high-frequency research, and received three batches of institutions during the period.
The annual net profit of Dazu Laser in 2018 is expected to increase by 0~20%. In the survey, the company briefly introduced the overall operation and competitive advantages of its PCB division in the first three quarters; Mindray Medical expects to achieve a net profit of 3.533 billion yuan to 3.905 billion yuan in 2018, a year-on-year increase of 36% to 51%. The company responded to 16 questions from the organization during the survey, including the future.MergerPlan, R&D investment, whether there is pressure on product price reduction in the future, etc.
Mindray Medical said that the company will continue to pay attention to the M&A opportunities in the market, taking into account various factors such as the quality of the target, the price of the target, and the synergy effect. In recent years, the company has insisted on about 10%.Operating incomeInvesting in research and development, launching 7 to 12 new products every year, with more than 2,000 R & D personnel; As for product price reduction pressure, Mindray Medical said that with the decline in raw material costs, existing products will have a certain degree of price reduction every year. At the same time, the company continues to introduce new products and maintain a price system. In the long run, the company mainly reduces costs through research and development and material procurement, and continues to introduce new products to maintain hair.interest rateLevel.
(Article source: Securities Times)